Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

嵌合抗原受体 Blinatumoab公司 医学 内科学 CD19 挽救疗法 肿瘤科 免疫疗法 免疫学 细胞疗法 抗原 化疗 干细胞 癌症 生物 遗传学
作者
Kitsada Wudhikarn,Jessica Flynn,Isabelle Rivière,Mithat Gönen,Xiuyan Wang,Brigitte Sénéchal,Kevin J. Curran,Mikhail Roshal,P. Maslak,Mark B. Geyer,Elizabeth Halton,Claudia Diamonte,Marco L. Davila,Michel Sadelain,Renier J. Brentjens,Jae H. Park
出处
期刊:Blood [American Society of Hematology]
卷期号:138 (7): 531-543 被引量:37
标识
DOI:10.1182/blood.2020009515
摘要

Abstract CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a breakthrough treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, despite the high initial response rate, the majority of adult patients with B-ALL progress after CD19 CAR T-cell therapy. Data on the natural history, management, and outcome of adult B-ALL progressing after CD19 CAR T cells have not been described in detail. Herein, we report comprehensive data of 38 adult patients with B-ALL who progressed after CD19 CAR T therapy at our institution. The median time to progression after CAR T-cell therapy was 5.5 months. Median survival after post–CAR T progression was 7.5 months. A high disease burden at the time of CAR T-cell infusion was significantly associated with risk of post–CAR T progression. Thirty patients (79%) received salvage treatment of post–CAR T disease progression, and 13 patients (43%) achieved complete remission (CR), but remission duration was short. Notably, 7 (58.3%) of 12 patients achieved CR after blinatumomab and/or inotuzumab administered following post–CAR T failure. Multivariate analysis revealed that a longer remission duration from CAR T cells was associated with superior survival after progression following CAR T-cell therapy. In summary, overall prognosis of adult B-ALL patients progressing after CD19 CAR T cells was poor, although a subset of patients achieved sustained remissions to salvage treatments, including blinatumomab, inotuzumab, and reinfusion of CAR T cells. Novel therapeutic strategies are needed to reduce risk of progression after CAR T-cell therapy and improve outcomes of these patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大橙子给暴躁的黎云的求助进行了留言
1秒前
1秒前
幽默不愁完成签到,获得积分10
1秒前
上官若男应助zqq采纳,获得10
1秒前
jebert发布了新的文献求助10
2秒前
2秒前
4秒前
上官若男应助lsy采纳,获得10
4秒前
独特的高山完成签到 ,获得积分10
5秒前
gigi发布了新的文献求助10
5秒前
白云朵儿发布了新的文献求助10
7秒前
大力的契完成签到,获得积分10
8秒前
8秒前
9秒前
荧惑发布了新的文献求助10
10秒前
11秒前
12秒前
邢夏之完成签到 ,获得积分10
12秒前
森林木发布了新的文献求助10
13秒前
jphu发布了新的文献求助10
13秒前
3123939715完成签到,获得积分10
14秒前
LMDD发布了新的文献求助10
14秒前
14秒前
15秒前
16秒前
七彩祥云兔完成签到,获得积分10
17秒前
111完成签到,获得积分10
18秒前
jxt完成签到,获得积分10
19秒前
19秒前
21秒前
gigi关注了科研通微信公众号
22秒前
个性思真完成签到,获得积分10
22秒前
lsy发布了新的文献求助10
22秒前
领导范儿应助jphu采纳,获得10
23秒前
24秒前
25秒前
aaa发布了新的文献求助10
25秒前
25秒前
鲨鲨鲨完成签到,获得积分10
26秒前
30秒前
高分求助中
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
行動データの計算論モデリング 強化学習モデルを例として 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2547977
求助须知:如何正确求助?哪些是违规求助? 2176407
关于积分的说明 5604321
捐赠科研通 1897193
什么是DOI,文献DOI怎么找? 946780
版权声明 565419
科研通“疑难数据库(出版商)”最低求助积分说明 503913